Biobeat Wearable Wrist and Chest Patient Monitoring Solutions Receives Class II Medical Device Approval from Health Canada

October 27, 2020

Biobeat provides wearable remote patient monitoring solutions for the healthcare continuum. Today they announced today that its wearable wrist and chest patient monitoring solutions have received Class II medical device approval (No. 320337) from Health Canada.

Biobeat reports their wireless wrist and chest monitoring solutions support health teams by transmitting real-time patient data from a distance, helping improve patient outcomes via accurate and reliable patient health updates and patient deterioration detection. These remote capabilities can be instrumental in helping monitor a variety of health conditions as well as mitigating the risk of infectious exposure, especially from COVID-19 patients.

“We are excited to receive the Health Canada Medical Device Class II approval, a significant milestone for our company, which will allow us to offer our innovative technologies to the Canadian healthcare market and help improve patient care,” said Arik Ben Ishay, CEO of Biobeat. “This registration underscores our mission to improve patient outcomes across the globe with our accurate wearable continuous patient monitoring solutions. We are eager to assist Canadian healthcare facilities and medical staff manage their patient workloads by using our advanced remote care abilities, especially during the current coronavirus pandemic.”

Maisha Labs, a Canadian digital health solution provider and integrator, assisted Biobeat throughout the licensing process and will continue to play a pivotal role in implementing the company’s solutions in healthcare facilities throughout the country. This includes an upcoming pilot project at The Jewish General Hospital and its Montreal-based Connected Health Futures Hub – OROT, orchestrated by a joint collaboration between Biobeat, Maisha Labs and the TransMedTech Institute, which will use Biobeat’s devices in a remote chronic care program.

Biobeat’s wearable wrist and chest-monitors utilize proprietary non-invasive reflective photoplethysmography monitoring technology to automatically and continuously track multiple vital signs and health parameters. The wireless solutions connect to a cloud-based patient management system to provide medical staff with real-time data and alerts, enabling early identification of clinical deterioration. The management platform includes an integrated automated, customizable early warning score system that incorporates advanced health-AI-based algorithms that analyze aggregated patient data to identify deterioration more accurately.

SourceBiobeat

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.